HUTCHMED
Strategic collaboration for Tazverik in Greater ChinaHUTCHMED
ASCO 2021: Moving towards combinationsHUTCHMED
Hong Kong listing number 13 is a potent symbolHUTCHMED
≥$600m Hong Kong IPO and global offer (104m shares)HUTCHMED
Baring Private Equity Asia invests $100mHUTCHMED
Breaking new ground in China and globallyHutchison China MediTech
Transitioning to a global oncology playerHutchison China MediTech
China approval clears Sulanda in epNETHutchison China MediTech
Canada Pension Plan invests $100m at $30 per ADSHutchison China MediTech
ESMO 2020: SANET-p delivers further positive suru data